Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02760485 · ClinicalTrials.gov registry record · Phase 1
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT02760485 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 33 participants.
The verdict
NCT02760485, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety/tolerability and efficacy of itacitinib in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Interventions
- DRUG ibrutinib
- DRUG itacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-12-29 |
| Est. Completion | 2022-06-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02760485
The ClinicalTrials.gov registry entry for NCT02760485 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ibrutinib is the first listed.
NCT02760485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02760485 about?
NCT02760485 is a clinical study titled "A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma". The purpose of this study is to evaluate the safety/tolerability and efficacy of itacitinib in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
What is the current status of trial NCT02760485?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2016-12-29. Estimated completion is 2022-06-06.
What interventions are being tested in trial NCT02760485?
The interventions under investigation include: ibrutinib (DRUG), itacitinib (DRUG).
Who is sponsoring clinical trial NCT02760485?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.